
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Jennifer Goldman, PharmD, CDE, BC-ADM, FCCP, professor of pharmacy practice at MCPHS University, discusses some barriers patients may have to starting insulin.
Jennifer Goldman, PharmD, CDE, BC-ADM, FCCP, professor of pharmacy practice at MCPHS University, discusses some barriers patients may have to starting insulin.
This video was recorded at APhA's Annual Meeting and Exposition in March 2015.






